AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01432119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: 100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
Study NCT01432119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
Study NCT01432119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
Study NCT01432119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Break-Through Scan
Description: Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.
Study NCT01437449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m² by intravenous (IV) administration
Study NCT01437449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m² by intravenous (IV) administration
Study NCT01437449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m² by intravenous (IV) administration, thereafter 250 IV
Study NCT01437449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
Study NCT03491605 — intervention group
Intervention type: OTHER
Intervention: peripheral EBV-DNA load
Description: No intervention
Study NCT02922803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 combination tablet of Vitamin D3/calcium per day
Description: Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
Study NCT02922803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 combination tablets of Vitamin D3/calcium per day
Description: Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
Study NCT00001651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [6,6-2H2]-glucose
Description: \[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
Study NCT03848533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)
Study NCT03848533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)
Study NCT03848533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)
Study NCT03848533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)
Study NCT03848533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)
Study NCT00634608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Information Prescription
Description: The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
Study NCT00875680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoPPC
Description: To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
Study NCT01714128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Description: FES-PET/CT imaging
Study NCT02243033 — intervention group
Intervention type: DEVICE
Intervention: MR-guided laser focal therapy
Description: Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
Study NCT01640691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (H5N1)
Description: Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)
Study NCT00360529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Study NCT00360529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flibanserin
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Study NCT04465006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy Simulator
Description: Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
Study NCT04465006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
Study NCT04730297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol 500 mg plus codeine 30 mg preoperative administration
Description: each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
Study NCT04730297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg preoperative administration
Description: each patient 30 minutes before surgery received ibuprofen 400 mg
Study NCT04730297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet preoperative administration
Description: each patient 30 minutes before surgery received placebo
Study NCT03652753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
Study NCT03652753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
Study NCT02157038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Study NCT02157038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03103555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
Study NCT03103555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
Study NCT02649868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Description: Transarterial embolization
Study NCT02649868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead LUMI
Description: LC Bead LUMI has been designed as a radiopaque version of the LC Bead
Study NCT04074980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous and Fingerstick blood draws
Description: Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
Study NCT04074980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venepuncture to collect blood samples from subjects
Study NCT01055366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elazop (Azarga)
Description: Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
Study NCT02534857 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: a shorter exposure of oocyte to spermatozoa
Description: Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Study NCT02534857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a shorter exposure of oocyte to spermatozoa
Description: Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Study NCT03297840 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dialectical Behavioural Therapy (DBT)
Description: Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
Study NCT01445899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 (Stratum I)
Description: PF-04523655 (a small interfering RNA) - a single IVT injection
Study NCT01445899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 6 monthly IVT injections of ranibizumab (Stratum II)
Study NCT01445899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 6 monthly IVT injections of ranibizumab (Stratum II)
Study NCT01445899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 (Stratum II)
Description: 6 monthly IVT injections of PF-04523655 (a small interfering RNA)
Study NCT03708198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Bupivacaine
Description: intercostal block
Study NCT01438866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealant
Description: Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
Study NCT01438866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealants and fluoride varnish
Description: Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
Study NCT02289300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1202
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study NCT02289300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study NCT02289300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1202+Placebo
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Study NCT04417959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phaco-DSAEK
Description: The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
Study NCT04417959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phaco-DMEK
Description: The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
Study NCT01218438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% Solution
Description: Intravenous infusion with IGIV, 10%
Study NCT01218438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human), 20% Solution
Description: Subcutaneous infusion with IGSC, 20%
Study NCT05999994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT04170959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
Study NCT04170959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No metformin
Description: Standard of care without metformin.
Study NCT02879747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
Study NCT02998333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stabilization
Description: Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
Study NCT03853083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoxi Equipment
Description: Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
Study NCT03853083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recumbent Bicycle
Description: Recumbent bike is a piece of exercise equipment used as the comparison group
Study NCT01119976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced calorie diet and exercise plan
Description: Participants will receive written diet and exercise instructions to follow for the duration of the study.
Study NCT01119976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different reduced calorie diet and exercise plan
Description: Participants will receive written diet and exercise instructions to follow for the duration of the study.
Study NCT02683187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Sitagliptin
Description: Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
Study NCT02683187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - No Sitagliptin
Description: Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
Study NCT03220763 — intervention group
Intervention type: OTHER
Intervention: This is an observational study--there is no intervention.
Description: This is an observational study, there is no intervention.
Study NCT01427075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LATERAL PHARYNGOPLASTY
Description: tonsilectomy and lateral pharyngoplasty
Study NCT01697293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01697293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01697293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01697293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01697293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
Study NCT01697293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine Phosphate
Description: Given IV
Study NCT01133652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veinviewer
Description: Veinviewer machine
Study NCT01133652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound
Study NCT01133652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional IV placement by nurses
Study NCT02040402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugated vaccine
Description: Pneumococcal vaccine 3+1 and 2+1 schedule comparison
Study NCT02040402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugated vaccine
Description: 3+1 doses vs 2+1 doses
Study NCT03118960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Bed
Description: This is an automatic rotational system in a bed designed to disburse capillary pressure
Study NCT03118960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group II Low Air Loss/Alternating Pressure Mattress
Description: Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
Study NCT02587351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Extended release Metoprolol succinate
Study NCT02587351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03815721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette r2x+
Description: device for repetitive transcutaneous spinal cord stimulation
Study NCT02300714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique view approach
Study NCT00613951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
Study NCT00613951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c., twice daily
Study NCT00613951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 1500-2000 mg/daily
Study NCT00613951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/daily
Study NCT03353818 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Golf
Description: A free golf course and free membership for one year in a golf club will be given to participants.
Study NCT03353818 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Patients acting as controls will not be restricted in any ways.
Study NCT03080129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresubin energy
Description: dietary protein energy supplement
Study NCT03998527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)
Description: TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.